So glad I was able to introduce @ForeignCinemaSF to @AngusMcQuilken and the @McDermottLaw team, not to mention @kwameulmer, for an amazing #JPM23 #BioWeekSF dinner!

So glad I was able to introduce @ForeignCinemaSF to @AngusMcQuilken and the @McDermottLaw team, not to mention @kwameulmer, for an amazing #JPM23 #BioWeekSF dinner!

RT @victoriacyanide
From #JPM23: @GileadSciences to initiate TWO ph3 trials with #GS5245 (#obeldesivir):

OAKTREE: in standard risk patients, incl pts in the US

BIRCH: high risk pts VERSUS PLACEBO, which is already enrolling (NCT05603143)

#GS441524 prodrug! 💊

https://s29.q4cdn.com/585078350/files/doc_presentation/2023/01/GILD-JPM-Presentation-9-January-2023.pdf

RT @vasudevbailey@twitter.com

23/ New strategies in diagnostics on display at #JPM23 - Freenome’s Mike Nolan highlights partnering with CVS and Cerner to increase accessibility. @freenome@twitter.com @CVSHealth@twitter.com @Cerner@twitter.com
https://www.fiercebiotech.com/medtech/jpm23-what-has-pandemic-done-us-freenome-and-other-diagnostics-developers-making-tests-more

🐦🔗: https://twitter.com/vasudevbailey/status/1614041262784675840

RT @vasudevbailey@twitter.com

22/ #JPM23 presentation by @KarunaPharma@twitter.com shows hope for KarXT NDA submission mid-2023 and to start phase 3 of ADEPT-2 trial and phase 3 of the ADEPT-3 trial in 2023 in treatment of schizophrenia.
https://twitter.com/KarunaPharma/status/1613179218795581440
https://www.nature.com/articles/s41398-022-02254-9

🐦🔗: https://twitter.com/vasudevbailey/status/1614041201279406081

RT @vasudevbailey@twitter.com

16/ What’s better than a planned $200 genome price tag? A $200 genome that’s already available. @ElemBio@twitter.com announces their new sequencing system during #JPM23:
https://twitter.com/ElemBio/status/1613194406848258048

🐦🔗: https://twitter.com/vasudevbailey/status/1614040658209308672

2023 is looking to be a breakout year for Lumen; even more non-dilutive funding, and 4 or more drugs in the clinic, all due to an integrated biologics design and manufacturing platform powered by electricity that economically outcompetes everything else by orders of magnitude.
---
RT @LumenBio
Jonathan D. Grinstein speaks with Brian @Finrow (Lumen, CEO) at #JPM23

Read the full article below,

https://www.genengnews.com/industry-news/re…
https://twitter.com/LumenBio/status/1613985615640686593

Antibody design is hard! Dunbrack and Gray have been doing excellent work for years in Rosetta including CDR redesign in the lab. Biswas is raising an important set of questions here at #JPM23 about claims of de novo design that don’t seem supported by the redesign data published. https://mobile.twitter.com/surgebiswas/status/1613232556673224705

https://pca.st/episode/cf34236b-d896-4631-b169-e41e3807bf0a With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in #biotech ahead, and whether the industry's biggest annual gathering might finally have outgrown its host city. #jpm23

Had a great time at #JPM23 this week meeting with friends, clients and partners passionate about helping patients live a better life.

Did storms steal JPM's thunder? —Oramed's oral insulin flunks phase 3 diabetes test, sending stock down 70% — FDA no longer needs to require animal tests before human drug trials -- See more on our front page news http://bit.ly/w28kSd #california #sanfrancisco #jpm2023 #jpm23 #oralinsulin #diabetes #type2diabetes #clinicaltrials #fda #animalresearch #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma

Interesting reaction to the @abscibio@twitter.com antibody design paper !

RT @SurgeBiswas@twitter.com

I usually let this stuff go, but this is too over the top

In splashy #JPM23 PR, @abscibio@twitter.com claim they can de novo design antibodies from scratch, but they actually design just the CDR3 (of 6 total) of existing Tx antibodies to their orig targets.

That's not de novo design

🐦🔗: https://twitter.com/SurgeBiswas/status/1613232556673224705

RT @bradloncar@twitter.com

📽️Kicking off day 3 of #JPM23 with someone I feel like I've known for years, @skathire@twitter.com. We talk LDL lowering, PCSK9, and base editing.

Note: there is brief noise towards the end after a guy walked in front and killed the mic signal so be careful if listening on headphones.

🐦🔗: https://twitter.com/bradloncar/status/1613204053961617408

RT @matthewherper@twitter.com

Big Verily news:

-15% of jobs cut
-@dramyabernethy@twitter.com is the new chief medical officer
-Jess Mega and Vivien Lee have left.

A lot of thoughts from the new CEO on its new direction in this memo.

https://www.statnews.com/2023/01/11/verily-alphabet-layoffs-jessica-mega-vivian-lee/

#JPM23

🐦🔗: https://twitter.com/matthewherper/status/1613277861196201984

Looking past Humira, AbbVie boosts sales forecasts for successor drugs — JPM23, Day 3: Takeda relishing in-person meetups — AstraZeneca and Avillion win approval for new asthma rescue treatment in adults -- See more on our front page news http://bit.ly/w28kSd #jpm2023 #jpm23 #humira #abbvie #takeda #asthma #astrazeneca #fda #biotech #biotechnology #biopharma #pharma #pharmanews #cafepharma

Our CEO just presented at #JPM23 – you can check it out here!
👉 https://ascidian-tx.com/publications-and-presentations/

Interesting slide from @BertrandBio (attending #JPM23 I aussume) concerning biosimilar patent stretch with Entyvia.

How Big Pharma gets 3-5y of add. peak sales for almost nothing in the US, in 1 slide: #SystemFAIL

https://twitter.com/BertrandBio/status/1612766357724057601

#patents #biosimilars #pharmaceuticals

RT @bradloncar
For #JPM23, I’m turning my Twitter into “Biotech TV.” Will be recording discussions with a ton of top newsmakers and industry leaders. Can’t wait to see many of you IRL and hope those who aren’t able to be in SF enjoy some of the content.🧬📺

RT @endpts
Our #JPM23 panel on “AI in biopharma 2023” is about to begin. Click below to tune in, and watch this thread for highlights. https://jpm23.endpts.com/

RT @RasuShrestha
“More important than “free capital” is “free people”.”

#JamieDimon, CEO @jpmorgan talking about the unique advantage of 🇺🇸

#JPMHC23 #innovation #JPM23 $JPM